Actively Recruiting
Effect of Testofen on Erectile Function in an Adult Male Population
Led by RDC Clinical Pty Ltd · Updated on 2025-07-24
120
Participants Needed
1
Research Sites
214 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a double blind, randomised, placebo-controlled clinical study with a 12-week participation and 3 groups (2 active groups and 1 placebo group) designed to monitor erectile function symptom severity and the effect Testofen may have on improving erectile function, sexual function, and quality of life.
CONDITIONS
Official Title
Effect of Testofen on Erectile Function in an Adult Male Population
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy male adults aged 40-75 years
- Currently in a sexual relationship
- Reduced erectile function with an International Index of Erectile Function (IIEF) score less than 25
- Body Mass Index (BMI) of 35 or less
- Able to provide informed consent
- Agree to maintain current diet and exercise program during the study
- Agree not to participate in another clinical trial during the study
You will not qualify if you...
- History of prostate surgery and/or trauma
- Receiving or prescribed treatment for erectile dysfunction, including oral medications, vacuum devices, constrictive devices, injections, or urethral suppositories
- Receiving or prescribed treatment to increase or decrease testosterone levels (e.g., androgens or anti-androgens)
- Receiving or prescribed treatment to alter nitrate or nitric oxide levels
- Having unstable or serious illnesses such as serious mood disorders, neurological disorders (e.g., MS), kidney disease, liver disease, heart conditions, diabetes, or hormone production disorders
- Current malignancies (excluding basal cell carcinoma) or recent chemotherapy/radiotherapy within the past 2 years
- Receiving anticoagulation therapy such as warfarin, heparin, or related treatments
- Active smokers, nicotine users, or persons with alcohol or drug abuse
- Chronic alcohol use exceeding 14 alcoholic drinks per week
- Allergic to any ingredients in the active or placebo capsules
- Any condition that the investigator deems makes participation unsuitable
- Participation in another related clinical study within the past month
- Participants told by their doctor they have hormone production disorders such as under or overproduction of hormones (e.g., testosterone)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
RDC Clinical Pty Ltd
Brisbane, Queensland, Australia, 4006
Actively Recruiting
Research Team
A
Amanda Rao, PhD
CONTACT
D
David Briskey, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here